Introduction {#s1}
============

Spliceosomes consist of the U1, U2, and U4/U6.U5 small nuclear ribonucleoproteins (snRNPs) and multiprotein Prp19-complex as major building blocks, plus many transiently interacting splicing factors ([@bib33]). This machinery recognizes and assembles stepwise at splice sites (SS) (U1 at 5\'SS and U2 at the 3\'SS/branch site) to form pre-spliceosomes, which are subsequently remodeled into catalytically active spliceosomes. Pre-spliceosomes can form on multi-intron pre-mRNAs through at least two different pathways. An intron can be recognized a) via cross-intron interactions leading directly to a catalytically active spliceosome, or b) via cross-exon interactions where the exons flanking an intron are first defined, after which cross-intron interactions between adjacent cross-exon complexes lead to spliceosome assembly ([@bib20]). On human pre-mRNAs, which characteristically harbor multiple long introns and short exons, exon definition predominates ([@bib3]; [@bib8]). Indeed, splicing is greatly enhanced when a 5\'SS is present across the exon downstream of an intron, highlighting the importance of exon definition in humans ([@bib32]; [@bib36]). Cross-exon pre-spliceosomes can transition into cross-intron pre-spliceosomes, each having a distinct protein composition; the latter can then productively splice the pre-mRNA ([@bib6]; [@bib27]). However, the mechanisms by which cross-intron and cross-exon pre-spliceosomes work together to facilitate pre-mRNA splicing remain unclear. In *S. cerevisiae*, where the cross-intron pathway predominates, single-molecule approaches have proven invaluable for elucidating the kinetic pathways and subcomplex dynamics involved in spliceosome assembly ([@bib28]; [@bib34]). Here we developed the tools necessary to implement colocalization single-molecule spectroscopy (CoSMoS) in human cell extracts and used this system to investigate the dynamic mechanism of cross-intron and cross-exon cooperation in human pre-spliceosome assembly.

Results {#s2}
=======

Single-molecule visualization of spliceosome assembly and function in human cell extract {#s2-1}
----------------------------------------------------------------------------------------

We began by investigating whether human nuclear extracts can assemble catalytically-competent spliceosomes on surface-tethered pre-mRNA molecules. To do this, we utilized the pre-mRNA model substrate PIP85A ([@bib21]) ([Figure 1A](#fig1){ref-type="fig"}, [Table 1](#table1){ref-type="table"}). We refer to this RNA here as '*5i3'* to indicate that, reading in the 5\'-to-3\' direction, it contains a partial exon, a 5\'SS (*'5'*), an intron (*i*), a 3\'SS (*'3'*), and another partial exon. For this pre-mRNA 20 ± 2% (s.d.) was converted to spliced products after 40 mins in human cell line HEK293 nuclear extract ([Figure 1B](#fig1){ref-type="fig"}). No spliced products were observed in the absence of ATP, which is required for spliceosome assembly. To monitor splicing of individual *5i3* molecules, we incorporated a green-excited dye into the 5\' exon, a red-excited dye into the intron, and biotin at the end of the 3\' exon ([Figure 1C](#fig1){ref-type="fig"}). We sparsely deposited this pre-mRNA onto a streptavidin-functionalized glass surface, added nuclear extract and followed green and red fluorescence from single pre-mRNA molecules over time. To exclude pre-mRNAs that lost intron signal due to RNA degradation, we selected only those molecules retaining 5\' exon (green) fluorescence at the end of the 40 min experiment. Of these, 1.1 ± 0.7% (s.e.) lost intron (red) fluorescence in a control conducted in the absence of ATP (likely due to photobleaching) whereas 18 ± 4% (s.e.) lost intron fluorescence in the presence of ATP. This single-molecule assay specifically monitors intron release, while the bulk assay measures the second splicing step. Intron release requires an ATP-dependent structural rearrangement of the splicing machinery after the second splicing step, so as expected the lag phase was somewhat longer in the single-molecule assay ([Figure 1C](#fig1){ref-type="fig"}) than in the bulk splicing assay ([Figure 1B](#fig1){ref-type="fig"}). However, surface-tethered *5i3* pre-mRNA molecules were spliced with a similar efficiency (17%) to what is observed in solution (20%).

![Observing splicing of the PIP85A (*5i3*) model pre-mRNA (**A**) in bulk (**B**) and single-molecule (**C**) splicing assays.\
Introns and exons are schematized as blue lines and rectangles, respectively, with A indicating the branchpoint. For bulk analysis (**B**) trace-labeled *5i3* was incubated with nuclear extracts, aliquots were analyzed on denaturing gel (15%) and second step splicing products quantified in graph. Second step splicing efficiency (±s.d.) was calculated as the amount of ligated exon product relative to the amount of *5i3* starting material at time zero. For single-molecule analysis (**C**), dyes tethered to the surface (red, green stars) were visualized using total internal reflection fluorescence microscopy using alternating red and green laser excitation (arrows); dye-labeled molecules in solution are not detectable. Fraction (±s.e.) of labeled introns remaining was calculated as the fraction of the N molecules retaining the exon dye fluorescence (green star) through the entire experiment duration which retained intron dye fluorescence (red star) at a particular time. Labeling of spliceosomal subcomplexes is shown in [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"}--[5](#fig1s5){ref-type="fig"}.](elife-37751-fig1){#fig1}

To enable single-molecule visualization of individual spliceosomal subcomplexes, we generated three HEK293 cell lines, each stably expressing C-terminally fSNAP-tagged U1-70K, U2B', or Snu114 at a level comparable to the endogenous protein ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Co-immunoprecipitation experiments confirmed efficient incorporation of the tagged protein into U1, U2, or U5 respectively ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Treatment of nuclear extracts with a green-excited dye-benzylguanine conjugate resulted in highly specific labeling of the fSNAP-tagged proteins ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). Because spliceosomal subcomplex concentrations in human nuclear extracts exceed the low dye concentrations optimal for single-molecule fluorescence, we labeled the tagged proteins using a limiting dye concentration (200 nM). Under these conditions, 30%, 60%, and 50% of total (tagged plus untagged) U1-70K, U2B', and Snu114 were labeled, respectively ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). Importantly, all tagged and dye-labeled extracts exhibited bulk splicing efficiencies comparable to extracts from the untagged parental cell line ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}).

Assembly of cross-intron and cross-exon pre-spliceosomes {#s2-2}
--------------------------------------------------------

We next used the labeled extracts in CoSMoS experiments in which we compared subcomplex dynamics on individual RNAs designed to promote assembly of cross-intron or cross-exon pre-spliceosomes ([Figure 2A](#fig2){ref-type="fig"}). The cross-intron RNA (*5i3*, [Figure 2B](#fig2){ref-type="fig"}) was identical to that in [Figure 1](#fig1){ref-type="fig"} except that it contained a single red-excited dye adjacent to the biotin tether at the end of the 3\' exon. An identically-labeled cross-exon RNA (*3e5*, [Figure 2B](#fig2){ref-type="fig"}) was constructed by swapping the 5\' and 3\' halves of *5i3*. Thus, *5i3* and *3e5* consist of identical sequence segments, and differ only by whether the 5\' and 3\'SS are separated by an intron (*i*) or an exon (*e*). Simultaneous presence of the two RNA species at distinct, known locations on the slide surface allowed us to compare their behavior under identical experimental conditions within a single reaction chamber ([Figure 2C](#fig2){ref-type="fig"}). After introducing extract containing dye-labeled U1, we monitored the binding and dissociation of labeled U1 to individual RNA molecules and to control locations that had no RNA (e.g., [Figure 2D](#fig2){ref-type="fig"}). Similar experiments were performed using U2- and U5-labeled extracts.

![CoSMoS monitoring of spliceosomal subcomplex interactions with individual cross-intron (*5i3*) and cross-exon (*3e5*) pre-mRNA molecules in human nuclear extracts.\
(**A**) Schematic of a CoSMoS experiment in which green dye-labeled U1 is observed binding to red dye-labeled, surface-tethered RNAs. Introns and exons are schematized as blue and magenta lines and rectangles, respectively, with A indicating the branchpoint. Dyes (stars) linked to tethered RNAs were visualized using total internal reflection fluorescence microscopy using alternating red and green laser excitation (arrows); dye-labeled molecules in solution are not detectable. (**B**) Schematic of *5i3* and *3e5* RNAs, with features indicated as in (**A**). See [Table 1](#table1){ref-type="table"} for RNA sequences. (**C**) Protocol: *5i3* (blue) and *3e5* (magenta) RNAs were sequentially deposited and located (squares) under red laser excitation. Non-overlapping control 'no RNA' locations (gray) were selected. Then, extract was introduced and spliceosomal subcomplex (e.g., **U1**) binding to individual RNA molecules was visualized under green laser excitation. Images (grayscale) are a small portion (2.6 μm x 2.6 μm) of the microscope field of view recorded at each stage of the process. See [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"} for complete field of view. (**D**) Time series images (1 s per frame; 1.3 μm x 1.3 μm) of U1 fluorescence from example surface locations containing a single *5i3* RNA (top), a single *3e5* RNA (middle) or no detected RNA (bottom). Images with fluorescence spots (highlighted) indicate U1 binding. See [Figure 2---figure supplement 4](#fig2s4){ref-type="fig"} for additional traces and detected events. (**E**) Rastergrams aggregating U1, U2, and U5 binding time courses from random samples of 50 individual *5i3* and *3e5* RNA molecules over 2,400 s. Each row in these plots contains data from a single RNA molecule; color indicates presence and white indicates absence of bound spliceosomal subcomplex. In each panel, RNA molecules are sorted by the time of first subcomplex binding (latest to earliest); the percentage (±s.e.) of N observed RNA molecules that exhibited subcomplex binding during the experiment is indicated. Rastergrams for 'no RNA' control locations are shown in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}. (**F**) Cumulative distributions of U1, U2, and U5 dwell times on N observed *5i3* and *3e5* RNAs or control 'no RNA' locations. Data show the mean frequency per RNA molecule (or per 'no RNA' location) of subcomplex binding events with durations greater than or equal to the indicated dwell time. All frequencies on RNAs are substantially higher than the non-specific binding seen at 'no RNA' locations (note logarithmic scale). (**G**) Total frequencies (±s.e.) per RNA molecule of RNA-specific subcomplex binding. These RNA-specific binding frequencies correspond to the RNA minus the no RNA vertical axis intercepts of the curves in (**F**); they represent the total rate of subcomplex-RNA binding throughout the 2,400 s experiment averaged over all observed RNA molecules. (**H**) Frequencies (±s.e.) per RNA molecule of the subsets of RNA-specific subcomplex binding events shorter or longer than 50 s. (**I**) Specific occupancy (±s.e.), corresponding to the fraction of RNA molecules bound by the indicated fluorescent subcomplex averaged over the duration of the experiment. Numbers of RNA molecules observed in (**G--I**) are the same as those reported in (**F**). The specific occupancy values are calculated as described (see Materials and methods) to correct for the small amount of binding observed at 'no RNA' locations. Source data for [Figure 2](#fig2){ref-type="fig"}: SourceDataFigure2.zip.\
10.7554/eLife.37751.012Figure 2---Source data 1.Data from the single-molecule experiments.](elife-37751-fig2){#fig2}

To quantitatively characterize subcomplex binding to the surface tethered RNAs, we measured both the frequency of RNA-specific subcomplex binding events and the steady-state fractional occupancy RNA molecules by the subcomplex. U1 binding to *5i3* RNA was highly dynamic with many arrivals and departures per active RNA molecule ([Figure 2E--G](#fig2){ref-type="fig"}) and a high frequency of short (\<50 s) binding events ([Figure 2F and H](#fig2){ref-type="fig"}). In comparison, progressively fewer *5i3* molecules bound U2 and U5 and the average occupancy of RNAs by these subcomplexes was also progressively lower ([Figure 2F and I](#fig2){ref-type="fig"}). Observed binding events were almost entirely RNA-specific; fewer and only short-duration binding events were observed at control 'no RNA' locations ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Overall, the kinetics of human spliceosomal subcomplex binding and dissociation on the cross-intron *5i3* substrate were similar to those observed in CoSMoS experiments on cross-intron RNAs in *S. cerevisiae* extracts ([@bib15]; [@bib29]).

Spliceosomal subcomplex interactions with the cross-exon *3e5* RNA were quantitatively different from interactions with the cross-intron *5i3* RNA. *3e5* RNA molecules exhibited more frequent binding events ([Figure 2F and G](#fig2){ref-type="fig"}) and higher mean occupancy ([Figure 2I](#fig2){ref-type="fig"}) for all subcomplexes than *5i3* molecules. These differences might be partially explained by the inability of the cross-exon pre-mRNA to form a catalytically active spliceosome ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), resulting in the greater accumulation of inactive spliceosome assembly intermediates at steady state. Consistent with this idea, U1, U2 and U5 exhibited a higher frequency of long-lived (\>50 s) binding events on the splicing-inactive *3e5* RNA than on the spliceable cross-intron *5i3* RNA ([Figure 2H](#fig2){ref-type="fig"}). In addition, possible differences between *5i3* and *3e5* three-dimensional structures could also alter the kinetics of their interactions with snRNPs.

We next investigated the effects of SS consensus sequence mutations on U1 and U2 binding dynamics. We restricted alterations to short consensus subcomplex binding sequences to reduce the possibility of the mutations causing large-scale changes in the three-dimensional structures of the RNAs. Functional U2 association with pre-mRNA depends on a polypyrimidine tract and the 3\'SS AG ([@bib26]). As expected, multiple pyrimidine to purine substitutions within the polypyrimidine tract combined with a 3\'SS AG to GG mutation ([Figure 3A](#fig3){ref-type="fig"}) greatly decreased the frequencies of RNA-specific U2 binding events, reducing binding to near-background levels ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). U1 binding, however, was largely unaffected by these mutations, with U1 specific association frequencies and dwell time distributions on *5iX* and *Xe5* RNAs indistinguishable from those on *5i3* and *3e5*, respectively ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Thus, consistent with previous cross-intron data in yeast ([@bib31]), human U1 binding is independent of U2 binding in both cross-intron and cross-exon contexts.

![Interdependence of U1 and U2 binding to cross-intron and cross-exon RNAs.\
(**A**) Schematics of *5i3* and *3e5* RNAs without or with polypyrimidine tract and 3\'SS mutations (**X**). See [Table 1](#table1){ref-type="table"} for RNA sequences. (**B**) Dynamics of dye labeled U1 binding to the RNAs depicted in (**A**), in a CoSMoS experiment in which all four RNAs were simultaneously present. Cumulative dwell time distributions and frequencies of RNA-specific binding were measured and plotted as in [Figure 2F and G](#fig2){ref-type="fig"}. For clarity, pairs of distributions are plotted in separate left and right panels and the no RNA data from the experiment is shown in both. Corresponding rastergrams are shown in [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}. (**C**) Schematics of *5i3* and *3e5* RNAs without or with 5\'SS mutations (**X**). (**D**) Dynamics of dye-labeled U2 binding in two separate CoSMoS experiments, one with *5i3* and *Xi3* RNAs (left) and one with *3e5* and *3eX* (right). Corresponding rastergrams are shown in [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}. Dependence of U1 binding on 5\'SS mutations and dependence of U2 binding on polypyrimidine tract and 3\'SS mutations are shown in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"} respectively. Source data for the single-molecule experiments in [Figure 3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}, [Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}, and [Figure 3---figure supplement 6](#fig3s6){ref-type="fig"}: SourceDataFigure3.zip, SourceDataFigure3S1.zip, SourceDataFigure3S3.zip, SourceDataFigure3S5.zip, and SourceDataFigure3S6.zip.\
10.7554/eLife.37751.022Figure 3---Source data 1.Data from the single-molecule experiments.](elife-37751-fig3){#fig3}
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###### RNAs.

5 N-U, 5-aminoallyluridine. U-DY547, Dylight 547 dye conjugated to C5 of U through a six-carbon linker. Small letters indicate mutated bases in the mutant sequence variants. The cryptic 5\'SS in *Xi3e5* (see [Figure 4B](#fig4){ref-type="fig"}) is underlined.

  -----------------------------------------------------------------------------------------
  RNA name                               RNA sequence (5\' to 3\')
  -------------------------------------- --------------------------------------------------
  *5i3* (cross-intron, PIP85A)           GGGCGAAUUCGAGCUCACUCUCUUCCGCAUCGCUGUCUGCG\
                                         AGGUACCCUACCAGGUGAGUAUGGAUCCCUCUAAAAGCGGG\
                                         CAUGACUUCUAGAGUAGUCCAGGGUUUCCGAGGGUUUCCG\
                                         UCGACGAUGUCAGCUCGUCUCGAGGGCGUACUAACUGGGC\
                                         CCCUUCUUCUUUUUCCCUCAGGUCCUACACAACAUACUGCA\
                                         GGACAAACUCUUCGCGGUCUCUGCAUGCAA

  *Xi3* (cross-intron, 5\'SS mutant)     GGGCGAAUUCGAGCUCACUCUCUUCCGCAUCGCUGUCUGCG\
                                         AGGUACCCUACCccccGAGUAUGGAUCCCUCUAAAAGCGGGCA\
                                         UGACUUCUAGAGUAGUCCAGGGUUUCCGAGGGUUUCCGUCG\
                                         ACGAUGUCAGCUCGUCUCGAGGGCGUACUAACUGGGCCCCUU\
                                         CUUCUUUUUCCCUCAGGUCCUACACAACAUACUGCAGGACAA\
                                         ACUCUUCGCGGUCUCUGCAUGCAA

  *5iX* (cross-intron, polypyrimidine\   GGGCGAAUUCGAGCUCACUCUCUUCCGCAUCGCUGUCUGCGA\
  tract and 3\'SS mutant)                GGUACCCUACCAGGUGAGUAUGGAUCCCUCUAAAAGCGGGCAU\
                                         GACUUCUAGAGUAGUCCAGGGUUUCCGAGGGUUUCCGUCGAC\
                                         GAUGUCAGCUCGUCUCGAGGGCGUACUAACUGGGCCgCUaCaU\
                                         gaUaUaCgCaCGGGUCCUACACAACAUACUGCAGGACAAACUCU\
                                         UCGCGGUCUCUGCAUGCAA

  *3e5* (cross-exon)                     GGGCGAAUUCGUCGACGAUGUCAGCUCGUCUCGAGGGCGUAC\
                                         UAACUGGGCCCCUUCUUCUUUUUCCCUCAGGUCCUACACAAC\
                                         AUACUGCAGGACAAACUCUUCGCGGUCUCUGCAUGCGAGCUC\
                                         ACUCUCUUCCGCAUCGCUGUCUGCGAGGUACCCUACCAGGU\
                                         GAGUAUGGAUCCCUCUAAAAGCGGGCAUGACUUCUAGAGUAG\
                                         UCCAGGGUUUCCGAGGGUUUCCAA

  *3eX* (cross-exon, 5\'SS mutant)       GGGCGAAUUCGUCGACGAUGUCAGCUCGUCUCGAGGGCGUA\
                                         CUAACUGGGCCCCUUCUUCUUUUUCCCUCAGGUCCUACACA\
                                         ACAUACUGCAGGACAAACUCUUCGCGGUCUCUGCAUGCGAG\
                                         CUCACUCUCUUCCGCAUCGCUGUCUGCGAGGUACCCUACCc\
                                         cccGAGUAUGGAUCCCUCUAAAAGCGGGCAUGACUUCUAGAG\
                                         UAGUCCAGGGUUUCCGAGGGUUUCCAA

  *Xe5* (cross-exon, polypyrimidine\     GGGCGAAUUCGUCGACGAUGUCAGCUCGUCUCGAGGGCGU\
  tract and 3\'SS mutant)                ACUAACUGGGCCgCUaCaUgaUaUaCgCaCgGGUCCUACACA\
                                         ACAUACUGCAGGACAAACUCUUCGCGGUCUCUGCAUGCGA\
                                         GCUCACUCUCUUCCGCAUCGCUGUCUGCGAGGUACCCUAC\
                                         CAGGUGAGUAUGGAUCCCUCUAAAAGCGGGCAUGACUUCU\
                                         AGAGUAGUCCAGGGUUUCCGAGGGUUUCCAA

  *5i3e5*                                GGGCGAAUUCGAGCUCACUCUCUUCCGCAUCGCUGUCUGC\
                                         GAGGUACCCUACCAGGUGAGUAUGGAUCCCUCUAAAAGCGG\
                                         GCAUGACUUCUAGAGUAGUCCAGGGUUUCCGAGGGUUUCC\
                                         GUCGACGAUGUCAGCUCGUCUCGAGGGCGUACUAACUGGG\
                                         CCCCUUCUUCUUUUUCCCUCAGGUCCUACACAACAUACUG\
                                         CAGGACAAACUCUUCGCGGUCUCUGCAUGCGAGCUCACUC\
                                         UCUUCCGCAUCGCUGUCUGCGAGGUACCCUACCAGGUGA\
                                         GUAUGGAUCCCUCUAAAAGCGGGCAUGACUUCUAGAGUA\
                                         GUCCAGGGUUUCCGAGGGUUUCCGACAAUUGCAUGAA

  *5i3eX*                                GGGCGAAUUCGAGCUCACUCUCUUCCGCAUCGCUGUCUG\
                                         CGAGGUACCCUACCAGGUGAGUAUGGAUCCCUCUAAAAGC\
                                         GGGCAUGACUUCUAGAGUAGUCCAGGGUUUCCGAGGGUU\
                                         UCCGUCGACGAUGUCAGCUCGUCUCGAGGGCGUACUAAC\
                                         UGGGCCCCUUCUUCUUUUUCCCUCAGGUCCUACACAACA\
                                         UACUGCAGGACAAACUCUUCGCGGUCUCUGCAUGCGAGC\
                                         UCACUCUCUUCCGCAUCGCUGUCUGCGAGGUACCCUACC\
                                         ccccGAGUAUGGAUCCCUCUAAAAGCGGGCAUGACUUCUA\
                                         GAGUAGUCCAGGGUUUCCGAGGGUUUCCGACAAUUGCAUGAA

  *Xi3e5*                                GGGCGAAUUCGAGCUCACUCUCUUCCGCAUCGCUGUCU\
                                         GCG[AGGU]{.ul}ACCCUACCccccGAGUAUGGAUCCCUCUAAAAG\
                                         CGGGCAUGACUUCUAGAGUAGUCCAGGGUUUCCGAGGG\
                                         UUUCCGUCGACGAUGUCAGCUCGUCUCGAGGGCGUACU\
                                         AACUGGGCCCCUUCUUCUUUUUCCCUCAGGUCCUACAC\
                                         AACAUACUGCAGGACAAACUCUUCGCGGUCUCUGCAUG\
                                         CGAGCUCACUCUCUUCCGCAUCGCUGUCUGCGAGGUAC\
                                         CCUACCAGGUGAGUAUGGAUCCCUCUAAAAGCGGGCAU\
                                         GACUUCUAGAGUAGUCCAGGGUUUCCGAGGGUUUCCG\
                                         ACAAUUGCAUGAA

  *Xi3eX*                                GGGCGAAUUCGAGCUCACUCUCUUCCGCAUCGCUGUC\
                                         UGCGAGGUACCCUACCccccGAGUAUGGAUCCCUCUAA\
                                         AAGCGGGCAUGACUUCUAGAGUAGUCCAGGGUUUCCG\
                                         AGGGUUUCCGUCGACGAUGUCAGCUCGUCUCGAGGGC\
                                         GUACUAACUGGGCCCCUUCUUCUUUUUCCCUCAGGUC\
                                         CUACACAACAUACUGCAGGACAAACUCUUCGCGGUCUC\
                                         UGCAUGCGAGCUCACUCUCUUCCGCAUCGCUGUCUGC\
                                         GAGGUACCCUACCccccGAGUAUGGAUCCCUCUAAAAGC\
                                         GGGCAUGACUUCUAGAGUAGUCCAGGGUUUCCGAGGG\
                                         UUUCCGACAAUUGCAUGAA

  S1                                     GGGCGAAUUCGAGCUCACUCUCUUCCGCAUCGCUGUCUG

  S2                                     CGAGGUACC(U-DY547)UACCAGGUGA

  S3                                     GUAUGGAUCCCUC(5 N-U)AAAAGCGGGCA(5 N-U)GACU\
                                         UCUAGAG(5 N-U)AGUCCAGGGUUUCCGA

  S4                                     GGGUUUCCGUCGACGAUGUCAGCUCGUCUCGAGGGCGU\
                                         ACUAACUGGGCCCCUUCUUCUUUUUCCCUCAGGUCCUA\
                                         CACAACAUACUGCAGGACAAACUCUUCGCGGUCUCUGCAUGCAA
  -----------------------------------------------------------------------------------------

Functional U1 association is blocked by mutation of the 5\'SS consensus from AG/GU to CCCC ([@bib25]). As expected, this mutation ([Figure 3C](#fig3){ref-type="fig"}) decreased the U1 association rate and eliminated RNA-specific long-duration (\>60 s) U1 binding events in both cross-intron and cross-exon contexts ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). Thus long-duration U1 binding events reflect its association with the canonical 5\'SS, as reported previously in *S. cerevisiae* extract ([@bib17]). In contrast, short duration U1 binding events are still present (although reduced in frequency) after 5\'SS mutation and may reflect sequence non-specific interactions with the RNA.

Surprisingly, the 5\'SS mutations affected U2 binding even more strongly than U1 binding. In both the cross-intron and cross-exon contexts, elimination of the canonical 5\'SS decreased U2 binding frequency to background within experimental uncertainty ([Figure 3D](#fig3){ref-type="fig"} and [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). Absence of U5 binding to these RNAs ([Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}) confirmed that the mutations abolished the formation of functional pre-spliceosomes. These observations could indicate that observable U2 binding requires the U1 binding to a 5\'SS positioned either cross-exon or cross-intron. Alternatively the results could also be explained if the 5\'SS mutation indirectly affects U2 binding by affecting the pre-mRNA secondary structure. To exclude the latter possibility, we demonstrated U2 binding to the 5i3 and 3e5 was also eliminated in experiments ([Figure 3---figure supplement 6](#fig3s6){ref-type="fig"}) in which U1 interaction with the 5\'SS was blocked by the addition of a morpholino oligonucleotide antisense to the U1 snRNA ([@bib16]). We conclude that U2 binding to the 3\'SS is strongly dependent on U1 binding to a 5\'SS either upstream (cross-intron) or downstream (cross-exon). This suggests an ordered human pre-spliceosome assembly pathway in which stable U2 association in the presence of ATP requires prior U1 binding, in contrast to the branched pathway observed in *S. cerevisiae* ([@bib29]).

Synergistic effects of cross-intron and cross-exon 5\'SS on pre-spliceosome assembly {#s2-3}
------------------------------------------------------------------------------------

In multi-intron pre-mRNAs, internal exons have 5\'SS both upstream and downstream, either or both of which could bind U1 and act to recruit U2 to the 3\'SS. In principle, the two U1s could act either independently or synergistically. If there is only one means by which U1 can recruit U2 (e.g., via binding to a single site on U2), the combined effect of two U1s on U2 binding would be at most the sum of their individual actions ([@bib14]). Such is the case for the activities of multiple SR proteins on splicing efficiency ([@bib13]). In contrast, if the upstream and downstream U1s can interact with U2 simultaneously, or if they accelerate different steps in the overall U2 recruitment process, their combined effect could be larger, that is, synergistic. Such synergy was previously observed between two distinct sequence elements within a regulated splicing enhancer ([@bib19]).

To determine whether the upstream and downstream 5\'SS independently or synergistically promote U2 binding, we constructed a pre-mRNA with 5\'SS both upstream and downstream of the 3\'SS (*5i3e5*, [Figure 4A](#fig4){ref-type="fig"}) as well as RNAs with mutations in either one 5\'SS (*Xi3e5* and *5i3eX*) or both (*Xi3eX*). In these constructs, the sequences flanking both 5\'SS were identical, minimizing potential sequence context effects. Consistent with the concept of exon definition ([@bib32]), splicing of *5i3e5* was 5-fold more efficient than *5i3eX* in ensemble splicing reactions ([Figure 4B](#fig4){ref-type="fig"}). In fact, the effect of adding the downstream 5\'SS was strong enough to activate an otherwise dormant cryptic 5\'SS in the *Xi3e5* construct. As expected, no splicing was observed on *Xi3eX* RNA.

![Synergistic recruitment of U2 by 5\'SS across introns and exons.\
(**A**) Schematic of *5i3e5* RNAs without or with 5\'SS mutations (**X**). Black brackets indicate two regions (113 nts) of identical sequence. (**B**) Ensemble splicing time courses of ^32^P-labeled RNA. Second step splicing efficiencies (±s.d.) were calculated as fraction of *5i3e5*, *5i3eX*, *Xi3e5* and *Xi3eX* starting material at time zero. Arrow indicates 5\' exon resulting from usage of a cryptic 5\'SS 12 nts upstream of the canonical 5\'SS in *Xi3e5*. (**C**) Cumulative dwell time distributions, RNA-specific binding frequencies (±s.e.) and time-averaged fractional occupancies (±s.e.) of U2 binding to *5i3e5*, *5i3eX*, *Xi3e5* and *Xi3eX* RNAs measured in the same experiment. Corresponding rastergrams are shown in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}. Analysis of time of first U2 binding event distributions is shown in [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}. Source data for the single-molecule experiments in [Figure 4](#fig4){ref-type="fig"}: SourceDataFigure4.zip.\
10.7554/eLife.37751.031Figure 4---Source data 1.Data from the single-molecule experiments.](elife-37751-fig4){#fig4}

We next performed single-molecule observations of U2 binding to these same four RNAs, all tethered and observed in a single reaction chamber to facilitate their direct comparison. Consistent with the observation that U2 binding in the cross-intron and cross-exon contexts depends on a 5\'SS ([Figure 3C and D](#fig3){ref-type="fig"}), no U2 binding above background levels was observed for the RNA with no 5\'SS (*Xi3eX*) ([Figure 4C](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Additionally, the shapes of the U2 dwell time distributions on *5i3eX* and *Xi3e5* ([Figure 4C](#fig4){ref-type="fig"}) were similar to those of the shorter *5i3* cross-intron and *3e5* cross-exon constructs ([Figure 2F](#fig2){ref-type="fig"}). Thus, the 5\'SS dependence of U2 binding seen with the longer RNAs was qualitatively similar to that observed on the previously characterized shorter RNAs.

Striking differences were apparent, however, when we compared the single 5\'SS RNAs (*Xi3e5* and *5i3eX*) to the double 5\'SS RNA (*5i3e5*) ([Figure 4C](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The presence of flanking 5\'SS both upstream and downstream of the 3\'SS dramatically increased U2 recruitment, with the RNA-specific U2 binding event frequency being more than 2.5 times the sum of the frequencies observed when either the upstream or downstream 5\'SS was present alone. A similar effect was seen in the U2 occupancy measurements ([Figure 4C](#fig4){ref-type="fig"}), although the occupancy data is more difficult to interpret due to splicing via the cryptic splice site in *Xi3e5*. A much greater than additive effect was also seen when we compared the distributions of the time to the first U2 binding observed on each RNA ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}), a metric that is comparatively immune to artefacts from spot detection dropouts ([@bib11]). Taken together, these data indicate that the upstream and downstream 5\'SS act synergistically to accelerate the rate of stable U2 recruitment to the 3\'SS.

Discussion {#s3}
==========

Here we establish methods for observing the dynamics of spliceosomal subcomplexes on and the splicing of individual pre-mRNA molecules in human cell extract. The experiments reveal that the dynamics of U1 binding to the 5\'SS are largely unaffected by the presence of U2 binding sites positioned either downstream (cross-exon) or upstream (cross-intron) of the 5\'SS. In contrast, stable U2 binding to the 3\'SS is accelerated by a 5\'SS situated across either the adjacent intron or adjacent exon. Strikingly, when functional 5\'SS are present together at both cross-intron and cross-exon locations, they synergistically promote U2 recruitment.

The more than additive effect of the flanking 5\'SS indicates that U1 employs different molecular mechanisms/interactions across introns and across exons to accelerate U2 recruitment. A simple model that would explain this observed synergy of cross-exon and cross-intron 5\'SS on U2 recruitment rate is that cross-exon U1 binding assists in recruiting the splicing factors that form a platform for U2 binding to the upstream 3\'SS region, whereas the cross-intron U1-U2 interaction favors a U2 conformation capable of productive branch site engagement ([Figure 5](#fig5){ref-type="fig"}, left). Across exons, U1 is known to recruit U2AF (U2 auxiliary factor), which recognizes the polypyrimidine tract and 3\'SS AG, and physically interacts with other proteins (e.g., SF1, p14, SF3B and SR proteins) required for stable U2 binding ([@bib4]). Across introns, U1 and U2 can interact via the DEAD-box protein Prp5, the ATPase activity of which promotes a structural change in U2 that makes the branch site recognition sequence more solvent accessible ([@bib1]; [@bib23]; [@bib35]). A different and not necessarily mutually exclusive model is that cross-exon and cross-intron U1 interactions could both help form the binding platform for U2, but by interacting with different proteins (e.g., the upstream U1 stabilizes SF1 and the downstream U1 stabilizes U2AF) ([@bib4]). This arrangement would increase the likelihood of U2 encountering a fully assembled binding platform when in a conformation capable of stable branch site engagement ([Figure 5](#fig5){ref-type="fig"}, right). Other mechanisms for synergy, such as those mediated by effects on RNA secondary structure, are also possible.

![Implications of synergistic U2 recruitment for the mechanism of exon and intron recognition.\
The cartoon illustrates how differing modes of U1 action from upstream (cross-intron) and downstream (cross-exon) sites can synergize to promote faster U2 binding when both flanking U1 sites are present. Double-headed arrows denote physical interactions in which one component may accelerate association or slow dissociation of another.](elife-37751-fig5){#fig5}

Models of the type presented in [Figure 5](#fig5){ref-type="fig"} assume that once a functional U1-U2 pre-spliceosome forms across the intron, interactions with U1 bound to the downstream 5\'SS provide no additional U2 binding stabilization or stimulation of subsequent steps of spliceosome assembly ([Figure 5](#fig5){ref-type="fig"}, bottom). Such models predict that the presence of a downstream U1 will not affect the lifetimes of stable U2 complexes once formed. The data in [Figure 4C](#fig4){ref-type="fig"} are consistent with this prediction: both the overall shape of dwell time distributions and the ratios of binding frequency to occupancy are similar for the RNAs with (*5i3e5*: 1.0 ± 0.2 s^−1^) or without (*5i3eX*: 1.3 ± 0.9 s^−1^) the downstream site. Taken together, our data suggest that the synergistic stimulatory effect of the downstream 5\'SS on splicing is exerted at the U2 recruitment step and the processes that enable it, not at the subsequent steps of spliceosome assembly and splicing.

Inappropriate skipping of otherwise constitutive internal exons can occur with exceptionally low frequency (\~1 in 10^5^ splicing events) ([@bib9]). But the molecular mechanisms contributing to this remarkable accuracy were previously unclear. By implementing CoSMoS in extracts from human cells expressing genetically-tagged proteins, we here show that a major contributor to exon inclusion is collaboration between flanking 5\'SS. This collaboration dramatically increases the rate of stable U2 recruitment during pre-spliceosome formation. Cross-intron and cross-exon 5\'SS synergy on U2 recruitment rate explains how U1 can have such a strong effect on U2 recruitment despite its association with pre-mRNA being much more dynamic than U2. This mechanism is likely crucial for rapid definition of internal exons in multi-intron RNAs, enabling the human splicing machinery to avoid inappropriate exon skipping.

Materials and methods {#s4}
=====================

Nuclear extract preparation {#s4-1}
---------------------------

Stable HEK293 Tet-On Flp-In cell lines were generated to express fSNAP fusions of U1-70K, U2B\'\', and Snu114 at near endogenous levels as previously described ([@bib30]). Stable HEK293 Tet-On Flp-In cell lines were generated from the Flp-In T-REx−293 Cell Line (Invitrogen, R78007). The cells were purchased from Invitrogen and their resistance to Zeocin and their Flp-In competence were confirmed. No further authentication or mycoplasma contamination testing were performed. Plasmid pcDNA5-FRT-TetO-fSNAPc was generated by amplifying the open reading frame of fSNAP using PCR primers fSNAP-F and fSNAP-R ([Table 2](#table2){ref-type="table"}) and inserting into pcDNA5-FRT-TetO (Invitrogen) using the HindIII and XhoI restriction sites. Plasmids containing spliceosomal subcomplex protein-fSNAP fusions ([Table 3](#table3){ref-type="table"}) were generated by PCR amplification from HEK293 cDNA for U1-70K and U2B\'\', and from Kazusa DNA Research Institute cDNA clone ORK00375 ([@bib22]) for Snu114 using the specified primers ([Table 2](#table2){ref-type="table"}) and cloning the products into pcDNA5-TetO-fSNAPc using the KpnI and NotI restriction sites. Expression levels of the fSNAP fusion proteins were adjusted to endogenous level by inducing the U1-70K-fSNAP, U2B\'\'-fSNAP, and Snu114-fSNAP Flp-In cell lines with 6 ng/ml, 3 ng/ml, and 3 ng/ml Doxycycline (BD Biosciences, 631311), respectively. Parental cells were not induced. Nuclear extracts were prepared as previously described ([@bib18]). In brief, HEK293 cells were grown at 37°C 5% CO~2~ in DMEM medium supplemented with 10% FBS. Cells from 10 confluent 15 cm dishes were harvested and washed with ice cold PBS. Cells (900 µl) were resuspended in 900 µl Buffer A \[10 mM Tris, 1.5 mM MgCl~2~, 10 mM KCl and 0.5 mM DTT, pH 7.9 at 4°C, supplemented with complete protease inhibitor cocktail (Roche, 04693159001)\], transferred to a 2 ml Eppendorf tube, incubated for on ice 15 min and then disrupted by 10 passages through a 25 gauge needle. After centrifuging the lysate for 20 s at 12,000 × *g*, the nuclear pellet was resuspended in 450 µl Buffer C \[20 mM Tris, 25% (v/v) glycerol, 0.42 M NaCl, 1.5 mM MgCl~2~, 0.2 mM EDTA and 0.5 mM DTT, pH 7.9 at 4°C, supplemented with complete protease inhibitor cocktail (Roche, 04693159001)\] and rapidly stirred in a 2 ml round-bottom microcentrifuge tube with a 12.7 × 3 mm stir bar for 30 min. After clarifying the lysate by centrifuging for 10 min at 12,000 × *g*, the SNAP-Surface 549 dye-benzylguanine conjugate (New England BioLabs, S9112S) was added to the supernatant at a final concentration of 200 nM and incubated for 30 min at 30°C. After labeling, the supernatant was dialyzed 2 times for 2 hr each against Buffer E (20 mM Tris, 20% (v/v) glycerol, 0.1 M KCl, 0.2 mM EDTA and 0.5 mM DTT, pH 7.9 at 4°C). The dialysate (1 ml) was spun again for 10 min at 16,000 × *g* and frozen in liquid nitrogen. Typical total protein concentration was 8.5 mg/ml. For negative control experiments, extracts were depleted of ATP using Centri-sep spin columns (Princeton Separations, CS-901) ([@bib2]). A single preparation of each of the three extracts was used in all reported experiments.

10.7554/eLife.37751.033

###### Plasmids.

  --------------------------------------------------------------------------
  Plasmid name                     Description
  -------------------------------- -----------------------------------------
  pcDNA5-FRT-TetO                  [@bib30]

  pcDNA5-FRT-TetO-fSNAPc           open reading frame of fSNAP inserted\
                                   into pcDNA5-FRT-TetO using the HindIII\
                                   and XhoI restriction sites

  pcDNA5-FRT-TetO-U1-70K-fSNAPc    open reading frame of U1-70K inserted\
                                   into pcDNA5-FRT-TetO-fSNAPc using\
                                   the KpnI and NotI restriction sites

  pcDNA5-FRT-TetO-U2B\'\'-fSNAPc   open reading frame of U2B\'\' inserted\
                                   into pcDNA5-FRT-TetO-fSNAPc using\
                                   the KpnI and NotI restriction sites

  pcDNA5-FRT-TetO-Snu114-fSNAPc    open reading frame of Snu114 inserted\
                                   into pcDNA5-FRT-TetO-fSNAPc using\
                                   the KpnI and NotI restriction sites

  PIP85.A (=T7-5i3)                [@bib21],\
                                   T7 transcription template for *5i3*

  T7-3e5                           T7 transcription template for *3e5*

  T7-5iX                           T7 transcription template for *5iX*

  T7-Xi3                           T7 transcription template for *Xi3*

  T7-3eX                           T7 transcription template for *3eX*

  T7-Xe5                           T7 transcription template for *Xe5*

  T7-5i3e5                         T7 transcription template for *5i3e5*

  T7-5i3eX                         T7 transcription template for *5i3eX*

  T7-Xi3e5                         T7 transcription template for *Xi3e5*

  T7-Xi3eX                         T7 transcription template for *Xi3eX*
  --------------------------------------------------------------------------

RNA preparation {#s4-2}
---------------

Radioactively labeled pre-mRNA substrate PIP85A ([Table 1](#table1){ref-type="table"}) was synthesized by in vitro transcription as previously described with a m7G(5\')ppp(5\')G 5\' cap and \[α-^32^P\]UTP ([@bib21]).

Two color pre-mRNAs carrying a 3\' biotin ([Figure 1C](#fig1){ref-type="fig"}) were prepared by splinted ligation as previously described ([@bib7]; [@bib29]) using DNA oligonucleotides and RNA segments listed in [Tables 1](#table1){ref-type="table"} and [2](#table2){ref-type="table"}. Specifically, RNA segments S1 (with a m7G(5\')ppp(5\')G 5\' cap) and S4 were produced in vitro by transcription by T7 RNA polymerase of templates generated by PCR from the plasmid PIP85A using the PCR primers S1-T7-F and S1-R or S4-T7-F and S4-R respectively. S2 and S3 were purchased from Dharmacon. Prior to the ligation 5\' ends of S2, S3 and S4 were phosphorylated and S3 was labeled with AlexaFluor 647 NHS ester (Thermo Scientific, A20006) as previously described ([@bib7]; [@bib29]). For the final splinted ligation S1, S2, S3, S4 RNA segments and the ligation splint oligonucleotide were annealed. The ligation resulted in an RNA where the 5\' exon was labeled with a single green-excited dye (DY547) at position −7 relative to the 5\'SS, the intron was labeled with on average two red-excited dyes (AlexaFluor 647) at positions 18, 30 and/or 42 relative to the 5\'SS, and a single biotin was added to the 3\' end by Klenow extension with biotin-dCTP (Trilink Bio Technologies Inc, N5002) ([@bib5]; [@bib29]).

10.7554/eLife.37751.034

###### Oligonucleotides and antisense morpholino oligonucleotides (AMO).

m, 2\'-O-methyl ribonucleotide; 3ddN, 3\' dideoxy nucleotide.

  ------------------------------------------------------------------------
  Oligonucleotide name        Oligonucleotide sequence (5\' to 3\')
  --------------------------- --------------------------------------------
  fSNAP-F                     AGAGATAAGCTTTCCAGCGGTACCGAGCTCGGATC\
                              CAGCGGACCTAGGGAAACCTGCGGCCGCGGCTCCG\
                              GAGGCTCCGGCGGGAGCGGCATGGACAAAGACTGCGAAATG

  fSNAP-R                     ACAGATCTCGAGCTAACCCAGCCCAGGCTTGCCCAGTC

  U1-70K-F                    AGAGATGGTACCATGACCCAGTTCCTGCCGCCCAAC

  U1-70K-R                    ACAGATGCGGCCGCACTCCGGCGCAGCCTCCATC

  U2B'-F                      AGAGATGGTACCATGGATATCAGACCAAATCATAC

  U2B'-R                      ACAGATGCGGCCGCATTTCTTGGCGTATGTAATTTTC

  Snu114-F                    AGAGATGGTACCATGGATACCGACTTATATGATGAG

  Snu114-R                    ACAGATGCGGCCGCACATGGGGTAATTGAGCACAACATC

  ligation splint             ACATCGTCGACGGAAACCCTCGGAAACCCTGGACTACT\
                              CTAGAAGTCATGCCCGCTTTTAGAGGGATCCATACTCA\
                              CCTGGTAAGGTACCTCGCAGACAGCGATGCGGAAGAG

  S1-T7-F                     TAATACGACTCACTATAGGGCGAATTCGAGCTCAC

  S4-T7-F                     TAATACGACTCACTATAGGGTTTCCGTCGACGATGTCAGCTC

  S1-R                        mCmAGACAGCGATGCGGAAG

  S4-R                        mUmUGCATGCAGAGACCGCGAAG

  2-color RNA Klenow splint   GTTCCTTGCATGCAGAGACCGCGAAGAG/3ddC/

  *5i3* template-F            TAATACGACTCACTATAGGGCGAATTCGAGCTCAC

  *5i3* template-R            mUmUGCATGCAGAGACCGCGAAG

  *5i3* Klenow splint         GTTCTTCTTATTGCATGCAGAGACCGCGAAGAG/3ddC/

  *5i3* Klenow capture        CTCTTCGCGGTCTCTGCATGCAATAAGAAGAAC

  *3e5* template-F            TAATACGACTCACTATAGGGCGAATTCGTCGACG

  *3e5* template-R            mUmUGGAAACCCTCGGAAACCCTG

  *3e5* Klenow splint         GTTCTTCTTATTGGAAACCCTCGGAAACCCTGGA/3ddC/

  *3e5* Klenow capture        TCCAGGGTTTCCGAGGGTTTCCAATAAGAAGAAC

  *5i3e5* template-F          TAATACGACTCACTATAGGGCGAATTC

  *5i3e5* template-R          mUmUCATGCAATTGTCG

  *5i3e5* Klenow splint       GTTCTTATCTTATTCATGCAATTGTCGGAAACCCTC/3ddC/

  *5i3e5* Klenow capture      GAGGGTTTCCGACAATTGCATGAATAAGATAAGAAC

  control-AMO                 CCTCTTACCTCAGTTACAATTTATA

  anti-U1-AMO                 GGTATCTCCCCTGCCAGGTAAGTAT
  ------------------------------------------------------------------------

One-color pre-mRNAs ([Figures 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}) were labeled at the 3\' end by Klenow extension with both AlexaFluor 647 dUTP (Life Technologies, A32763) and biotin dCTP, resulting in one (*5i3* and *3e5*) or two (*5i3e5*) AlexaFluor 647 dyes and one biotin per pre-mRNA molecule. All oligonucleotides used for Klenow extensions are listed in [Tables 1](#table1){ref-type="table"} and [2](#table2){ref-type="table"}.

Western blotting {#s4-3}
----------------

Protein samples were separated by SDS-PAGE and transferred to a 0.45 μm pore size nitrocellulose membrane (Whatman, PROTRAN BA 85, 10 401 196). Proteins were detected using the indicated antibodies and an Odyssey CLx Imager (LI-COR) according to manufacturer's instructions.

Co-immunoprecipitation {#s4-4}
----------------------

Cells (one 15 cm dish per condition) were lysed in 3 ml Buffer 1 (10 mM Tris pH 7.4, 100 mM NaCl, 2.5 mM MgCl~2~) supplemented with 40 μg/ml digitonin. Nuclei were collected by pelleting at 2,000 × *g* for 10 min and resuspended in 3 ml Buffer 1 supplemented with 0.1% Triton X-100 and complete protease inhibitor cocktail (Roche, 04693159001). The suspension was sonicated (Branson Digital Sonifier-250) for 8 s in bursts of 2 s and the NaCl concentration adjusted to 150 mM. This nuclear lysate was clarified by centrifugation at 15,000 × *g* for 10 min and an input sample taken. Dynabeads Protein A (Life Technologies, 10002D) or Protein G (Life Technologies, 10001D) pre-incubated with respective antibodies were added and nutated for 2 hr. After four washes with Buffer 2 (20 mM Tris pH 7.4, 150 mM NaCl, 0.1% NP-40), bound proteins were eluted with SDS loading dye and analyzed by Western blotting as described above.

Fluorescence and Coomassie gels {#s4-5}
-------------------------------

Protein samples were separated by denaturing polyacrylamide gel electrophoresis (SDS-PAGE). Gels were fixed in 25% isopropanol and 10% acetic acid, and fluorescence was imaged using a Typhoon scanner (GE Healthcare). Gels were subsequently stained with Coomassie Brilliant Blue dye R-250 (Thermo Scientific, 20278) to visualize total protein.

Bulk in vitro splicing assays {#s4-6}
-----------------------------

Splicing reactions were performed at 30°C in 20 µl of 40% HEK 293 nuclear extract in final concentrations of 60 mM K^+^-MOPS pH 7.3, 2 mM ATP, 0.5 mM DTT, 2 mM MgOAc~2~, 20 mM potassium glutamate, 5 mM creatine phosphate, and 0.1 mg/ml *E.coli* tRNA with 20 fmol radioactively labeled pre-mRNA substrate. To make conditions correspond to those in the CoSMoS experiments, the bulk assays also included 0.9 U/ml *B. cepacia* protocatechuate dioxygenase (Sigma P8279; 5 U/mg; 9 mg/ml) and 5 mM protocatechuate (Sigma 37580, recrystallized from hot water before use) as an O~2~ scavenging system and 1 mM Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, Aldrich, 23,881--3) as a triplet quencher ([@bib15]). Where indicated, anti-U1 AMO or control AMO (Gene Tools, sequences are described in [Table 2](#table2){ref-type="table"}) were added at 10 µM final concentration as previously described ([@bib16]) and the splicing reaction was 20 min pre-incubated at 30°C prior to the addition of pre-mRNA substrate. After incubating at 30°C for times indicated, splicing reactions were stopped by adding 10 volumes of Stop Buffer (100 mM Tris-Cl^-^, 10 mM EDTA, 1% SDS, 150 mM NaCl, and 300 mM sodium acetate, pH 7.5). RNAs were extracted and separated by denaturing polyacrylamide (15%) gel electrophoresis. The dried gel was phosphorimaged with a Typhoon PhosphorImager and RNAs quantified using ImageQuant with signal intensities being normalized to their U content. Splicing efficiencies were calculated as the ratio of spliced RNA product (i.e., ligated exons) to pre-mRNA starting material at time zero.

Single molecule in vitro splicing assays {#s4-7}
----------------------------------------

Glass slides and cover slips were prepared as described previously ([@bib10]) except that PEGylation was only allowed to proceed for 3 hr at room temperature after which slides and coverslips were washed with 50 mM potassium phosphate buffer pH 7.4, dried with N~2~ gas and stored at −80°C until use. After assembly of reaction chambers with vacuum grease (up to five lanes per slide with a volume of \~25 µl each), individual lanes were rehydrated immediately before use with 50 mM potassium phosphate buffer pH 7.4.

Single-molecule fluorescence imaging used a micro-mirror total internal reflection fluorescence (TIRF) microscope with automatic focus ([@bib10]; [@bib15]). Sample temperature was maintained at 30°C using a custom-built temperature control system ([@bib24]). Streptavidin-conjugated fluorescent beads (Life Technologies, T10711) were tethered to the surface (multiple beads per field of view) and were used as reference for stage drift correction. RNAs were tethered on the slide surface at a total density of \~0.2--0.5 fluorescent spots per µm^2^. When multiple different RNA species were tethered sequentially, a microscope image was taken after each round of deposition to individually identify the molecules of each RNA species. Splicing reactions (60 µl) were assembled as described for the bulk assays above (but without pre-mRNA) and introduced into individual slide lanes by capillary action and wicking; imaging was initiated immediately after reaction loading. For experiments with the two color pre-mRNA we acquired a 1 s duration frame every 5 min with 150 μW 633 nm (red) excitation except at the beginning and end of the experiment when we acquired one frame per second with 300 μW 532 nm (green) excitation. For experiments with the one color pre-mRNAs and labeled nuclear extracts we acquired sequences of 100 one-second duration frames with 300 μW 532 nm excitation alternating with a single one-second frame with 150 μW 633 nm excitation. All excitation powers are measured incident to the input micro-mirror.

Single molecule data analysis {#s4-8}
-----------------------------

Data analysis was performed using custom software (<https://github.com/gelles-brandeis/CoSMoS_Analysis>; copy archived at https://github.com/elifesciences-publications/CoSMoS_Analysis) implemented in MATLAB (MathWorks) as previously described ([@bib11]; [@bib15]); locations of fluorescent spots were identified by image analysis using the spot-picker algorithm ([@bib11]). Locations of tethered RNA molecules and control locations were determined in drift-corrected, color-aligned images. For spliceosomal subcomplex detection, images were averaged with a five frame sliding window before spot picking. Binding frequencies were calculated as described ([@bib11]). The provided source data files are 'intervals' files readable by imscroll (<https://github.com/gelles-brandeis/CoSMoS_Analysis>). The time-averaged specific occupancy of RNA molecules by a spliceosomal subcomplex (i.e., the fraction of time the RNA a fluorescently labeled subcomplex is bound to the RNA) was calculated as (*f*~m~ - *f*~c~) / (1 - *f*~c~) where the subscripts m and c refer to RNA and no RNA control locations, respectively, and *f* represents the fraction of time that a fluorescent spot was present, averaged over all locations measured for each type. Note that this value underestimates the subcomplex occupancy since only a fraction of each subcomplex is labeled ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). Standard error of the fractional occupancy was determined by bootstrapping (2,000 random samples). Distributions of time to first binding event were fit to background-corrected single-exponential models as described ([@bib11]).
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Reviewer \#2:

This manuscript by Braun et al., describes an exciting and carefully executed set of experiments that provide direct evidence for a phenomena that has long been observed but difficult to quantitatively demonstrate. Specifically, this study uses the single molecule CoSMoS approach developed in the Moore and Gelles labs to investigate the role of cross-intron and cross-exon interactions in the binding of the U1 and U2 snRNP; an early step in the assembly of the spliceosome. Many previous studies have demonstrated that in mammalian systems, having binding sites for both U1 and U2 either across an intron or on either side of an exon promotes spliceosome assembly and, ultimately, splicing itself. This has been interpreted to indicate that U1 and U2 interact in a cross-intron or cross-exon manner to promote stable association of one or the other component. Previous studies with CoSMoS have called into question such cooperative assembly of U1 and U2 in yeast; however, here the authors address this question in a mammalian system.

The experiments are elegantly designed, in the use of consistent sequences in the various constructs and in the analysis of multiple substrate variants on the same slide to ensure all RNAs are experiencing the same conditions. Moreover, the major conclusion -- that stable association of U2 is synergistically promoted by both cross-intron and cross-exon interactions with U1 -- is well supported. One could ask for additional mutations outside the splice sites as controls (for instance in a *5i3e5* context), but it is unclear that this would really add much to the overall story.

One conspicuously absent piece of data is the binding of U1 to *3eX* or *Xi3eX*. At least the first of these is critical if the authors are going to conclude that \"U2 binding was even more strongly affected by the 5'SS mutations than U1\". It would also be interesting to know how mutation of a single 5'SS in the *5i3e5* context impacts dwell times and frequencies of U1 overall. Finally, the authors also should provide data for the association of U2 with *Xe5*. One might imagine that this mutation doesn\'t reduce U2 frequency much if it is recruited via interaction with U1. This would be an interesting observation.

Reviewer \#3:

In this manuscript, Braun et al. use single molecule fluorescence microscopy to study the formation dynamics of spliceosomal subcomplex assembly from human cell extracts. The authors measure the binding and dissociation kinetics between U1, U2 and U5 snRNPs and RNAs modelling cross-intron or cross-exon assembly. They use a surface immobilized pre-mRNA PIP81A. The same labs have pioneered the use of yeast cell extracts to study spliceosomal assembly at the single molecule level. Based on their data the authors propose that flanking U1 binding sites synergistically increase the rate of U2 binding.

Overall, the manuscript is well written and the experiments are technically sound. However, some of the conclusions in the manuscript appear to be only weakly supported by the data. In addition, aspects of the RNA change between experiments, making it difficult to make solid conclusions. For example, it is not clear how non-specific binding to non-splice sites affects the observed binding patterns, or how potential changes in secondary/tertiary structures have not been formally ruled out. Based on these issues, I cannot recommend publication of this manuscript in *eLife* in its current form. The conclusions may very well hold, but additional experiments/clarifications are need-ed in order to strengthen the paper.

Strengths

\- Single molecule splicing assays with mammalian cell extracts is an important step forward in the field, which has been limited to yeast cell extracts for about a decade.

\- The ability to begin addressing the question of cross-intron/exon spliceosomal assembly is important.

\- The approach to monitor multiple RNAs on the same slide and under the same conditions is a strength of the paper.

Weaknesses

\- All of the experiments presented here use a no-RNA control. In my mind this is not the best control for these experiments. An RNA with scrambled, modified or re-moved 5\' or 3\' splice sites should be used as a control instead.

\- It is clear that many of the \"short\" (\<50s) U1 binding events are non-specific. How these events are affecting the observed assembly pathways is an important question that needs to be solved in this manuscript. For example, control experiments with immunodepleted extracts (U1, etc.) could address this.

\- Although *5i3* and *3e5* consist of the same sequence elements the order of the elements could dramatically affect their secondary and tertiary structures. How do the structures of these RNA affect the observed results?

\- An important issue with the *3e5* experiments, is that there is no way to demonstrate that the observed binding events lead to bona fide splicing. Could the binding to these RNAs be completely off pathway?

\- In transcribed pre-mRNAs cross-intron and cross-exon spliceosome assembly will directly compete with each other, the observed higher stability of the cross-exon assembly would suggest that cross-intron assembly would not take place in many instances, potentially leading to aberrant splicing. How do the authors reconcile their results with this?

\- Subsection "Assembly of cross-intron and cross-exon pre-spliceosomes", last paragraph: A simpler explanation is that the secondary structure of the *Xi3* RNA prevents binding of the U2 sub-complex.

Reviewer \#4:

This manuscript describes a set of carefully designed single molecule experiments aimed at understanding spliceosomal component recruitment to introns and exons. The authors analyze U1, U2, and U5 association/dissociation dynamics in the context of an intron-defined pre-mRNA substrate, which can splice, and in the context of an exon flanked by functional splice sites, which cannot splice. The results of U1, U2 and U5 dynamics indicate that binding U1 is independent of U2 binding or of additional U1 binding sites. Interestingly, the data also show that U2 dynamics are significantly influenced by additional U1 binding. It is shown that the non-spliceable construct *3e5* exhibited higher U1, U2, and U5 occupancy when compared to the splicing competent *5i3*. The second major observation is that a downstream 5'SS (*5i3e5*) enhances splicing efficiency and U2 occupancy. When carrying out mutational analyses of *5i3e5*, deleting either 5'SS alone or in combination, the authors observe more than additive effects on U2 occupancy. The authors conclude that the presence of a downstream 5\' splice site synergistically promotes U2 recruitment.

The experiments presented examine in more detail previous observations and they provide novel insights. Several years ago, it was demonstrated that downstream 5\' splice sites have a positive effect on in vitro splicing (Chiara and Reed, 1995; Yue and Akusjarvi, 1999). It was argued then that their presence improves splicing much like splicing enhancers do. The present work takes such observations a step further by demonstrating that U2 occupancy is much improved. The manuscript should include a discussion of these previous works.

The main figures supporting the notion of synergy is Figure 4. Permutations of *5i3e5* were tested, either mutating one of the two 5'SS or both splice sites. Of concern here is the fact that *Xi3e5* (the upstream intronic 5'SS deleted) results in the activation of a cryptic splice site. *Xi3e5* is therefore no longer a substrate without an intronic 5'SS, but rather one that has a weaker intronic 5'SS. It is unclear to what degree the data obtained for this substrate may cloud the conclusions. By design, it was expected that this construct should not splice at all. Rather, the mutation should have rendered the splicing competent cross intron construct into a splicing incompetent cross exon construct, similarly as illustrated in Figure 2. Based on consistency expectations, one would have expected that the *Xi3e5* mutation display similar U2 occupancy as the *3e5* construct in Figure 2 -- relatively high or \~4-fold higher than what is observed. Using the authors own arguments for explaining the occupancy difference between the splicing competent and incompetent substrates *3e5* and *5i3* (Figure 2), the low U2 signal of *Xi3e5* could be caused by its undesired splicing activity. This discrepancy needs to be addressed as the entire argument of synergy rests in part on the *Xi3e5* occupancy data point.

10.7554/eLife.37751.044

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

We thank all three reviewers for their thorough analysis of our manuscript, and their many insightful and helpful comments. In response, we have added a substantial amount of new data and made numerous changes to the text. A summary of the major data additions is as follows:

1\) We added data for U2 binding to *3e5* and *Xe5* pre-mRNAs (now Figure 3---figure supplement 1D-F). These data confirm that U2 binding requires a polypyrimidine tract and 3\'SS also in the cross-exon context.

2\) We added data on U1 binding to *3e5* and *3eX* pre-mRNAs (now Figure 3---figure supplement 3D-F). These data confirm that long-duration U1 binding depends on a canonical 5'SS also in the cross-exon context.

3\) We added data showing that U5 binding to *5i3* pre-mRNA depends on the 5'SS (now Figure 3---figure supplement 5). These data confirm that the observed U5 binding events to *5i3* are sequence specific.

4\) We added data showing that an antisense morpholino oligonucleotide (AMO) targeting U1 snRNA strongly reduces U2 binding to both *5i3* and *3e5* RNAs (now Figure 3---figure supplement 6). These results strongly support the hypothesis that the 5'SS mutations suppress U2 binding act by disfavoring U1 binding to the 5'SS rather than by altering pre-mRNA secondary structure.

Our detailed responses to individual reviewers\' verbatim comments are given below:

> Reviewer \#2:
>
> \[...\] The experiments are elegantly designed, in the use of consistent sequences in the various constructs and in the analysis of multiple substrate variants on the same slide to ensure all RNAs are experiencing the same conditions. Moreover, the major conclusion -- that stable association of U2 is synergistically promoted by both cross-intron and cross-exon interactions with U1 -- is well supported. One could ask for additional mutations outside the splice sites as controls (for instance in a 5i3e5 context), but it is unclear that this would really add much to the overall story.

We agree that such mutations (presumably intended as negative controls) would not add much to the story. It is well established that there are effects of RNA sequences outside of the splice site consensus sequences on pre-spliceosome assembly, but comprehensive understanding of these is lacking. It would be difficult to rationally design such mutations and to interpret their effects.

> One conspicuously absent piece of data is the binding of U1 to 3eX or Xi3eX. At least the first of these is critical if the authors are going to conclude that \"U2 binding was even more strongly affected by the 5'SS mutations than U1\".

We have now added the requested data on U1 binding to *3eX* as Figure 3---figure supplement 3D-F. These data confirm that, just as was demonstrated for the cross-intron RNA (*5i3*), mutation of the 5\' splice site in the cross-exon context (*3e5*) essentially eliminates the long U1 binding events. With these new data, the statement quoted by the reviewer is now supported -- in both cross-intron and cross-exon constructs, 5\'-SS mutation reduces primarily long U1 binding events but reduces U2 binding events of all durations.

> It would also be interesting to know how mutation of a single 5'SS in the 5i3e5 context impacts dwell times and frequencies of U1 overall.

[Author response image 1](#respfig1){ref-type="fig"} shows new data demonstrating the effect of both single and double 5'SS mutations on U1 binding in the *5i3e5* context. As expected, mutation of both 5'SS\'s reduces the long-duration (\>\~75 s) binding events to background levels. Long binding event frequencies are similar on *5i3e5, Xi3e5*, and *5i3eX*. Thus, in contrast to what we observe for U2, there is no evidence of 5'SS synergy for U1 recruitment. Based on the data in the manuscript, we expected many of the short binding events to be 5'SS-independent, and *Xi3eX* had a high frequency of short binding events. Despite the fact that these data show the expected results, we feel that some caution is required in interpreting them as we cannot distinguish between the presences of one or two U1\'s bound to each RNA molecule. In summary, we are happy to show these data here, but because they don\'t lend themselves to any straightforward conclusions, we prefer to leave them out of the manuscript to avoid unnecessary distraction for the reader.

![U1 binding to four RNA constructs, all measured in the same experiment, analogous to the U2 data in Figure 4.](elife-37751-resp-fig1){#respfig1}

> Finally, the authors also should provide data for the association of U2 with Xe5. One might imagine that this mutation doesn\'t reduce U2 frequency much if it is recruited via interaction with U1. This would be an interesting observation.

We have now added the requested data on U2 binding to *Xe5* as Figure 3---figure supplement 1D-F. These data confirm that, just as was demonstrated for the cross-intron RNA (*5i3*), mutation of the 3\' splice site in the cross-exon context (*3e5*) greatly reduces (by \~10-fold) the frequency of U2 binding events. In our view, these results and the analogous cross intron results do *not* exclude a role of U1 in U2 recruitment, but simply show that U2 is usually not bound for long enough to be detected in our experiments unless a 3\'SS is present to stabilize its association with the RNA.

> Reviewer \#3:
>
> \[...\] Weaknesses
>
> \- All of the experiments presented here use a no-RNA control. In my mind this is not the best control for these experiments. An RNA with scrambled, modified or re-moved 5\' or 3\' splice sites should be used as a control instead.

The reviewer is correct that all of our experiments include a no RNA control; this control is important to make sure that we are correctly measuring the frequencies of binding to RNA molecules (both sequence-specific and sequence non-specific binding) as opposed to binding to the slide surface. Nonetheless, as suggested by the reviewer, the original manuscript also contained controls using RNAs with mutated splice sites. In the revised manuscript, we have now added even more controls of this type. Below is a detailed summary of the mutated splice site controls for experiments observing U1, U2, and U5 snRNPs. This list includes both controls present in the original manuscript and new experiments added in the revised version:

U2: Control experiments with *5iX* (Figure 3---figure supplement 1) and *Xe5* (now added to Figure 3---figure supplement 1D-F) show that mutation of the 3\'SS consensus sequences reduce U2 binding to background. This implies that none of the detected binding of U2 is sequence nonspecific. Rather, all observed U2 binding over the no RNA background is 3\'SS-dependent. Similarly, experiments with *Xi3* and *3eX* (Figure 3C,D) and *Xi3eX* (Figure 4C) show that mutation of the 5'SS consensus sequence(s) reduce(s) U2 binding to background. This again shows that none of the detected binding of U2 is sequence non-specific, and further reveals that all observed U2 binding over background is 5'SS-dependent.

U5: We have added new controls (Figure 3---figure supplement 5) showing that mutation of the 5'SS reduces U5 binding to background. This demonstrates that there is no detectable sequence non-specific binding of U5. Rather, as for U2, all detected U5 binding events depend on a 5'SS (presumably as a consequence of U1 binding there).

U1: Control experiments with *Xi3* (Figure 3---figure supplement 3A-C), *3eX* (now added as Figure 3---figure supplement 3D-F), and *Xi3eX* (shown in [Author response image 1](#respfig1){ref-type="fig"} in response to a comment by reviewer \#2) clearly show that long U1 binding events, but not short ones, depend on the canonical 5'SS. This is not surprising, since U1 has additional roles aside from of prespliceosome formation -- it is known to interact with proteins that bind the RNA cap structure, with proteins that bind the branch point, and with RNA sequences that diverge from the 5'SS consensus. Presumably most or all of the observed short binding events reflect these other interactions, as our experiments show that these short binding events are largely 5'SS independent. In contrast, the long events require the 5'SS, presumably due to sequence-specific interactions.

> \- It is clear that many of the \"short\" (\<50s) U1 binding events are non-specific. How these events are affecting the observed assembly pathways is an important question that needs to be solved in this manuscript. For example, control experiments with immunodepleted extracts (U1, etc.) could address this.

We agree that our data do not speak to the question of whether the short events are involved in pre-spliceosome assembly. The major point of the manuscript is to establish the synergy of cross-intron and cross-exon interactions in recruiting U2 to the pre-spliceosome. We respectfully suggest that it is not necessary to resolve the role of the short U1 binding events to reach that conclusion from the data. Nonetheless, we have revised the text to explicitly state that some or all of the short events may reflect sequence non-specific interactions of U1 with RNA. It is possible that these short U1 binding events are irrelevant to splicing. Alternatively, it might be that the short events report the formation of interactions (e.g., sequence-non-specific binding) that can assist with the ultimate formation of a stable interaction with the 5'SS. With regard to additional control experiments, it was unclear to us how immunodepletion experiments would resolve this point. Nevertheless, we have now added to the manuscript an experiment in which we prevented specific U1 binding to the 5'SS by preincubating the extract with an antisense morpholino oligo directed at the 5\' end of U1 snRNA.

> \- Although 5i3 and 3e5 consist of the same sequence elements the order of the elements could dramatically affect their secondary and tertiary structures. How do the structures of these RNA affect the observed results?

Yes, *5i3* and *3e5* could have different 2D and 3D structures despite containing the same sequence elements. We now explicitly state this in the manuscript (subsection "Assembly of cross-intron and cross-exon pre-spliceosomes"). However, an analysis of *5i3* and *3e5* RNA sequences using the Vienna RNA Websuite (Gruber et al., 2008 NAR 36:W70-4) for minimum free energy predictions suggests that *5i3* and *3e5* have very similar stability and structure elements as shown below.

The optimal secondary structure for *5i3* has a minimum free energy of **-**69.0kcal/mol. This structure is shown in [Author response image 2](#respfig2){ref-type="fig"} in dot-bracket notation with the second half highlighted in gray.

![Optimal secondary structure prediction for *5i3*](elife-37751-resp-fig2){#respfig2}

The optimal secondary structure for *3e5* has a minimum free energy of **-***67.4*kcal/mol. This structure is shown in [Author response image 3](#respfig3){ref-type="fig"} with the same sequence as in *5i3* highlighted in gray.

![Optimal secondary structure prediction for *3e5*](elife-37751-resp-fig3){#respfig3}

To aid comparison between the two structures, in [Author response image 4](#respfig4){ref-type="fig"} we have rearranged the halves to place them next to one another. The first line of dot-bracket notation is for *5i3* and the second is for *3e5*.

![Comparison of the optimal secondary structure predictions of *5i3* and *3e5*](elife-37751-resp-fig4){#respfig4}

This analysis shows that the base pairing and the overall stabilities of the most stable secondary structures of *5i3* and *3e5* are very similar. Of course, the possibility exists that these calculated lowest free energy structures do not accurately represent the structures assumed by these sequences in our experiments. Thus it is important to note that we base all essential conclusions of the paper on comparisons of a particular RNA construct *with the same construct containing a localized binding site mutation*. This greatly reduces (but, we acknowledge, does not entirely eliminate) the possibility that differences in 3D structure might contribute to some of the results. We have now added explicit discussion of this experimental design feature (i.e., use of binding site mutations) to the text (subsection "Assembly of cross-intron and cross-exon pre-spliceosomes").

> \- An important issue with the 3e5 experiments, is that there is no way to demonstrate that the observed binding events lead to bona fide splicing. Could the binding to these RNAs be completely off pathway?

The reviewer is correct that *3e5* does not splice (as is expected); the data confirming this can be found in Figure 2---figure supplement 4. Nevertheless, mutation of *3e5* to *3eX* essentially eliminates U2 binding as does mutation of *Xi3e5* to *Xi3eX* (compare Figure 3D, right to Figure 4C) and the experiments in Figure 4 demonstrate that both the upstream and downstream 5'SSs in *5i3e5* contribute synergistically to U2 recruitment and to splicing. Based on these data we think it reasonable to conclude that binding of U1 to the cross-exon 5'SS is on pathway for splicing of this RNA.

> \- In transcribed pre-mRNAs cross-intron and cross-exon spliceosome assembly will directly compete with each other, the observed higher stability of the cross-exon assembly would suggest that cross-intron assembly would not take place in many instances, potentially leading to aberrant splicing. How do the authors reconcile their results with this?

With respect to the higher stability of the cross-exon assembly, we assume that the reviewer is referring to the data of Figure 2I. As explained in the manuscript, these data do not indicate that cross-exon complexes are more stable than cross-intron, but merely show a higher steady-state concentration of the complexes due to the fact that there is no easy kinetic pathway out of the *3e5* complexes because they cannot splice. Furthermore, we are unaware of any basis for the suggestion that there is direct competition between cross-intron and cross-exon spliceosome assembly under conditions where splicing actually occurs. Indeed, it is not even clear that cross-exon and cross-intron complexes utilize the same binding surfaces on U2. The synergy we observe suggests that when a downstream, cross-exon 5'SS is present (i.e., in *5i3e5* vs. *5i3eX*), it greatly promotes both U2 recruitment and eventual splicing of the upstream intron rather than causing competition.

> \- Subsection "Assembly of cross-intron and cross-exon pre-spliceosomes", last paragraph: A simpler explanation is that the secondary structure of the Xi3 RNA prevents binding of the U2 sub-complex.

We have now added data to the manuscript reporting experiments where, rather than preventing U1 binding to the 5'SS by mutating the 5'SS consensus (which, as the reviewer points out, has the potential to alter the secondary structure of the pre-mRNA), we instead prevented U1 binding to the 5'SS by adding a morpholino oligo complementary to U1 snRNA (using the same reagent as Kaida et al., 2010 Nature 468:664-668). This manipulation suppresses U2 binding even more strongly than the 5'SS mutations on both 5i3 and 3e5 RNAs (these data now added as Figure 3---figure supplement 6). These results strongly suggest that the 5'SS mutations suppress U2 binding act by disfavoring U1 binding to the 5'SS rather than by altering pre-mRNA secondary structure.

> Reviewer \#4:
>
> \[...\] The experiments presented examine in more detail previous observations and they provide novel insights. Several years ago, it was demonstrated that downstream 5\' splice sites have a positive effect on in vitro splicing (Chiara and Reed, 1995; Yue and Akusjarvi, 1999). It was argued then that their presence improves splicing much like splicing enhancers do. The present work takes such observations a step further by demonstrating that U2 occupancy is much improved. The manuscript should include a discussion of these previous works.

Thank you for pointing out this oversight. We now cite these earlier results in the first paragraph of the revised manuscript.

> The main figures supporting the notion of synergy is Figure 4. Permutations of 5i3e5 were tested, either mutating one of the two 5'SS or both splice sites. Of concern here is the fact that Xi3e5 (the upstream intronic 5'SS deleted) results in the activation of a cryptic splice site. Xi3e5 is therefore no longer a substrate without an intronic 5'SS, but rather one that has a weaker intronic 5'SS. It is unclear to what degree the data obtained for this substrate may cloud the conclusions. \[...\] Using the authors own arguments for explaining the occupancy difference between the splicing competent and incompetent substrates 3e5 and 5i3 (Figure 2), the low U2 signal of Xi3e5 could be caused by its undesired splicing activity. This discrepancy needs to be addressed as the entire argument of synergy rests in part on the Xi3e5 occupancy data point.

We agree that this point required clarification; we have revised the final paragraph of the Results section accordingly. [Author response image 5](#respfig5){ref-type="fig"} and [6](#respfig6){ref-type="fig"} show graphs that aggregate the relevant data from Figures 2 and 4. With respect to the specific frequency (a measure of the apparent association rate constant of U2 with the different RNAs), *5i3* and *5i3eX* are similar, as expected. In contrast, *3e5* is \~2-fold lower than *Xi3e5*. Since the latter contains all of the sequence elements present in the former, the most likely explanation is that there may be some additional secondary structure present in the latter that modestly slows U2 binding. Because of the possibility of such structural alterations (as well as experiment-to-experiment variability), we specifically chose not to compare RNAs of different lengths to reach our conclusions about synergy. Instead we compare RNAs that are otherwise identical except for consensus binding site mutations, using only data collected at the same time in the same sample (that is, under precisely identical conditions). (This point is also discussed in response to comments of reviewer 3, above.) Note that because it measures the *association* rate, the frequency measurement in Figure 4C is not significantly affected by consumption of the complexes resulting from the slow cryptic splicing of *Xi3e5*. The same is true for the time to first binding measurements (Figure 4---figure supplement 2). For these reasons, we base our argument for synergy on these analyses, which specifically tell us about the rate of formation of detectable U2-RNA complexes. That is why we emphasize both in the abstract and in the concluding paragraph of the paper that our data demonstrate synergy in *U2 recruitment* rather than talking about synergy in, for example, stabilization of the pre-spliceosome subsequent to U2 binding.

In contrast to the frequency data, mechanistic interpretation of the specific occupancy data is more difficult because it is affected by multiple factors, including possibly by cryptic splicing as pointed out by the reviewer. We now say this explicitly in the final paragraph of the Results section.

![Total frequencies ( ± s.e.) per RNA molecule of RNA-specific U2 snRNP binding.\
Data are from Figures 2G and 4C.](elife-37751-resp-fig5){#respfig5}

![Fractional occupancy ( ± s.e.) of RNA molecules by U2 snRNP, averaged over the duration of the experiment.\
Data are from Figures 2I and 4C.](elife-37751-resp-fig6){#respfig6}
